Revelation Biosciences (REVB) Shares Outstanding (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Shares Outstanding (Entity) of $620785.0 for Q4 2025, up 4243.58% year-over-year from $14292.0 in Q4 2024, and down 6.11% quarter-over-quarter from $661183.0 in Q3 2025.
Revelation Biosciences (REVB) Shares Outstanding (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Shares Outstanding (Entity) for 6 consecutive years, with $620785.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 4243.58% year-over-year to $620785.0; the TTM figure through Dec 2025 stood at $620785.0 (up 4243.58% YoY), while the FY2025 annual figure was $620785.0, up 4243.58% from the prior year.
- Shares Outstanding (Entity) retreated to $620785.0 in Q4 2025 per REVB's latest filing, from $661183.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $661183.0 in Q3 2025 and bottomed at $9.0 in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $80489.1 across 5 years, with a median of $1093.0 in 2023.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) sank 59.09% — and 2025, when it soared 4636.95%.
- Revelation Biosciences' Shares Outstanding (Entity) stood at $9.0 in 2021, then jumped by 944.44% to $94.0 in 2022, then jumped by 1365.96% to $1378.0 in 2023, then soared by 937.16% to $14292.0 in 2024, then jumped by 4243.58% to $620785.0 in 2025.
- Business Quant data shows REVB's Shares Outstanding (Entity) at $620785.0 in Q4 2025, $661183.0 in Q3 2025, and $200668.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.83 Mn |
| Dec 31, 2025 | 620,785.00 |
| Sep 30, 2025 | 661,183.00 |
| Jun 30, 2025 | 200,668.00 |
| Mar 31, 2025 | 80,942.00 |
| Dec 31, 2024 | 14,292.00 |
| Sep 30, 2024 | 13,958.00 |
| Jun 30, 2024 | 8,517.00 |
| Mar 31, 2024 | 5,676.00 |
| Dec 31, 2023 | 1,191.00 |
| Sep 30, 2023 | 1,093.00 |
| Jun 30, 2023 | 1,009.00 |
| Mar 31, 2023 | 384.00 |
| Dec 31, 2022 | 94.00 |
| Sep 30, 2022 | 104.00 |
| Jun 30, 2022 | 75.00 |
| Mar 31, 2022 | 70.00 |
| Dec 31, 2021 | 9.00 |
| Sep 30, 2021 | 9.00 |
| Jun 30, 2021 | 9.00 |